centred around the value of bone-marrow transplantation in irradiation damage, leukaemia, and the anaemias, but, in addition, work has been focused on other possible uses and techniques for bonemarrow transplantation.
That bone-marrow transplantation was indeed a practicable proposition was learned from irradiation experiments on mice. It was found that the death which follows a high dose of X-irradiation could be circumvented by the administration of haemopoietic cells shortly after the irradiation episode (Lorenz et al., 1951) . This life-saving act could be performed not only by syngeneic cells, but also by allogeneic and even xenogeneic tissue (Lorenz and Congdon, 1954) . It was demonstrated that the survival was the result of the colonization of the irradiated mouse by the injected cells (Ford et al., 1956 ). These cells retained their genotypic identity in their new hosts and so produced a chimera.
Much was gleaned from the many experiments in this field, but above all there emerged one disturbing consequence. Whereas when the donor cells were syngeneic in origin, recovery was uneventful and permanent, with allogeneic cells, though there could be long-lasting success, recovery was often marred by the appearance of an illness called variously secondary disease, homologous disease, or runt disease. In the mouse the symptoms included dermatitis, a stunted and weedy Received 11 March 1970. 1 appearance, and diarrhoea, with splenomegaly and aplastic lymph nodes. The illness was often grave and could be fatal. It was established that the runting syndrome was caused by a graft versus host reaction (Billingham and Brent, 1959) , and the response was due to the fact that in the life-preserving inoculum some immunologically competent components attempted (sometimes successfully) to act against and reject the host.
Disregarding runting, one obvious application for bone-marrow transplantation seemed to be in leukaemia, with irradiation to kill the leukaemic cells followed by replacement of the depleted myeloid system with normal haemopoietic tissue. Initial experiments in a murine leukaemia were hopeful (Barnes et al., 1956 ), but subsequent experiments were not successful (Barnes and Loutit, 1957, and , for example, Maddock and Djerassi, 1958; Mathe, Amiel, and Bernard, 1960) . The main obstacle again seemed to be secondary disease. There is no doubt that the injected normal haemopoietic cells implant and function, but then the graft versus host action begins. Initially, this may be providential, as it reinforces the effects of the irradiation, aiding in the final eradication of the leukaemic cells. But later, as the graft versus host reaction progresses, it causes the death of the transplanted individual. Very often death from secondary disease anticipates that which would have resulted from the untreated leukaemia (Mathe, 1961) .
A more promising bone-marrow transplantation in animals is in myeloid insufficiency, and this, too, has some relevance to human disease. There are many known examples of this in the mouse. One is the genetically determined severe macrocytic anaemia found in mice of the W-series. In 1956, Russell, Smith, and Lawson irradiated these mice and administered syngeneic normal haemopoietic tissue, and subsequently obtained a normal blood picture. However, these workers were not able to transplant allogeneic tissue in their mice as they could not find a level of irradiation that would allow the acceptance of the foreign tissue without itself being lethal (Bernstein, Russell, and Lawson, 1959) . They found that when syngeneic tissue was used, 305 prior irradiation was not necessary for the success of the implant (Bernstein and Russell, 1959 (Seller and Polani, 1966) . Secondly, the mice were made tolerant to the genotype of the prospective donor, by an injection of lymphoid cells at birth and then treated with allogeneic haemopoietic cells when adult (Seller, 1968a) , and finally, adult anaemic mice were immunosuppressed with antilymphocytic serum (ALS) before treatment with the allogeneic cells (Seller and Polani, 1969) . These last two sets of experiments were conducted effectively with the human problem in mind. Whatever the regimen for the treatment, the outcome was always the same; there was a change in the peripheral blood picture from the anaemic type to one of a haematologically normal mouse, and this was maintained for the rest of their lives. Using both haemoglobins and chromosomes as markers, it was possible to detect the donor cells in the treated mice (Seller, 1966 (Seller, , 1968b . The studies with chromosomes showed that in the case of these homozygote mice, the donor cells completely replaced the defective host bone-marrow cells. As would be expected from this total myeloid replacement, the granulocytes were also of the donor type (Seller, 1968c) . Furthermore, the donor cells also came to constitute a large part of the dividing population of the spleen, thymus, and lymph nodes. In contrast to the bone-marrow, however, these organs retained a small core (5-20%) of host cells which were never eliminated.
The organs of the lympho-myeloid complex were colonized in a very definite sequence. After the injection of the haemopoietic cells, the spleen was the first organ to bear large numbers of dividing donor cells, and this was soon followed by the bonemarrow, then the thymus, and finally the lymph nodes (Seller, 1970b) . This donor cell invasion did not extend to every tissue of the body, however, for at least one, the cornea of the eye, remained solely of host type cells in the haemopoietic chimeras (Seller, in preparation) .
The heterozygote mice of the W series (genotype Wvw) are also anaemic, but are less severely affected than the homozygotes. These too were successfully transplanted and attained a normal blood picture (Seller, 1967) . In this case, the bonemarrow was not completely replaced; approximately 10% of the dividing population remained of the host type.
As far as the applicability to similar human anaemias is concerned, the only model which is practically possible as yet is the one involving the use of ALS, for the period of immunological incompetence in Man ends early in fetal life. However, ALS has the disadvantage that though it is a powerful immunosuppressive and permits the establishment of the foreign cells, it itself causes an anaemia (Seller and Polani, 1969 (Lance, 1968) . Therefore, individuals unsuccessfully grafted the first time can be treated with ALS and then regrafted. This has been achieved in the W-mice (Seller, in preparation) . Such possibilities must also offer hope for polytransfused humans.
The histocompatibility system in the mouse is as complex as in the human, with several loci and multiple alleles. Though the genetic relation between donor and host needs to be close, it appears that absolute identity between donor and recipient is not absolutely essential for successful bonemarrow transplantation. Russell and Bernstein (1967) have found acceptance of the bone-marrow graft in W anaemic mice when the donor differed from the host at a non H-2 locus, provided there was identity at the main H-2 locus. It is to be noted that in this situation skin grafts were rejected, albeit slowly, so the fate of skin grafts is not necessarily a reliable guide as to the potential success of a haemopoietic tissue graft.
A genetic disorder in the deer mouse, identical to human hereditary spherocytosis, has also been cured by bone-marrow transplantation (Steinmuller and Motulsky, 1967) , but another murine anaemiathe Steel anaemia-has been found by McCulloch et al. (1965) (Nowell and Defendi, 1964) . The disease can be reduced in severity by the administration of various immunosuppressive agents, for example amethopterin (Russell, 1961) or prednisone given at the same time as the haemopoietic cells, and methotrexate given at the time when the symptoms of the disease are expected (Schwartz and Beldotti, 1965) . ALS has come to the fore in this respect too. In mice, treatment of the donors with ALS before they surrender their haemopoietic tissue leads to almost complete prevention of secondary disease in irradiated recipients, yet there is no decrease in the survival rate of the mice (van Bekkum et al., 1967) . However, as yet, there should not be too much optimism, for secondary disease is still an important reason for failure in human bone-marrow transplantation. Van Bekkum et al. (1969) point out that there are basic differences in the secondary disease suffered by mice and men, notably in onset and severity. Monkeys resemble man much more closely in these aspects, and so perhaps non-human primates rather than rodents should be used for finally overcoming this particular problem.
Nature's own bone-marrow transplantation experiment in the form of fetal parabiosis resulting in chimerism, first observed in fraternal cattle twins (Owen, 1945) , suggested that parabiosis might be a usable technique. In mice, it is marginally successful when the histocompatibility differences are not great, for instance when the connected individuals differ in the Y-antigen (Lustgraaf, Fuson, and Eichwald, 1960) or other non H-2 loci (Martinez et al., 1960) . However, in allogeneic combinations, parabiotic intoxication, almost certainly another graft versus host reaction, occurs, leading to death of one partner (Cornelius, Yunis, and Martinez, 1967) .
Successful bone-marrow chimerism leads to immunological tolerance to the genotype of the donor of the haemopoietic cells. The marmoset, in which fraternal twinning with placental vascular anastomoses occurs so often as to be the rule has, of course, haemopoietic tissue chimerism in the resulting adults, and skin grafts exchanged between the twin pairs are accepted permanently (Porter and Gengozian, 1969) . Radiation chimeras (Main and Prehn, 1955) and transplanted anaemic mice (Seller, 1970a ) also accept skin grafts from the donor of the haemopoietic tissue, while grafts from individuals unrelated both to the bonemarrow donor and the host are rejected, showing that there is specific rather than non-specific suppression. This tolerant state is usually detected by skin grafts. But if skin is accepted, why not organs such as the kidneys and heart? This idea immediately makes bone-marrow transplantation of additional value, not only in itself as a form of therapy for bone-marrow disease but also as a starting block for organ transplantation. This would be important because tolerance is the ideal form of immunological unresponsiveness so far discovered, because of its specific non-reactivity. The cattle twins resulting from parabiosis with permanent erythrocyte chimerism may eventually reject (after about 230 days) skin grafts exchanged between the twin partners (Stone et al., 1965) , but it appears that reciprocal kidney grafts are probably tolerated (Cragle and Stone, 1967) . In an experimental situation, Grosjean Bone-marrow transplantation in animals can thus be done in various ways and for many disorders and often is impressively successful. But in the translation of these animal models to Man success seems to be lost. Human bone-marrow transplantation has been tried in various malignancies and some of the bone-marrow aplasias, such as thrombocytopenia, agranulocytosis, and some anaemias (see Pegg, 1966 (French and Batchelor, 1969) , and in humans to prevent maternal sensitization to fetal rhesus antigens (Clarke, 1967 
